Walther E K, Dahlmann N, Gorgulla H T
Universitäts-Hals-Nasen-Ohren-Klinik Bonn.
Laryngorhinootologie. 1990 May;69(5):271-4. doi: 10.1055/s-2007-998188.
The clinical relevance of the tumor-associated antigens SCC (squamous-cell carcinoma), CEA (carcinoembryonic antigen), and CA (carbohydrate antigen) 19-9 as tumor markers is evaluated. Twenty-six patients with squamous-cell carcinoma of the head and neck region were studied in a six-month period. Concentrations above 2 ng/ml (SCC), 5 ng/ml (CEA), and 37 U/ml (CA 19-9) are regarded as markers of abnormal activity. Elevated tumor markers were found only in 12-15%. No correlation between the serum levels and tumor localization, staging, grading, or general condition was detected for any of the markers. In the follow-up, they revealed no disease-related information despite treatment variation. The results obtained suggest that, given the present state of biochemical possibilities and considering the rather low sensitivity for head and neck cancer, the routine assessment of SCC, CEA, and CA 19-9 serum levels is of no account.
评估了肿瘤相关抗原鳞状细胞癌抗原（SCC）、癌胚抗原（CEA）和糖类抗原19-9（CA 19-9）作为肿瘤标志物的临床相关性。在六个月的时间里对26例头颈部鳞状细胞癌患者进行了研究。SCC浓度高于2 ng/ml、CEA高于5 ng/ml以及CA 19-9高于37 U/ml被视为异常活性标志物。仅12%至15%的患者发现肿瘤标志物升高。对于任何一种标志物，均未检测到血清水平与肿瘤定位、分期、分级或一般状况之间存在相关性。在随访中，尽管治疗方式不同，但它们并未揭示与疾病相关的信息。所获得的结果表明，鉴于当前的生化检测能力以及考虑到头颈部癌相对较低的敏感性，常规评估SCC、CEA和CA 19-9的血清水平并无意义。
